

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Lu et al. Art Unit : 1648
Serial No. : 10/728,195 Examiner : Bo Peng
Filed : December 3, 2003 Conf. No. : 7308
Title : POLYVALENT, PRIMARY HIV-1 GLYCOPROTEIN DNA VACCINES AND
VACCINATION METHODS

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications can be provided upon request.


This statement is being filed after a first Office action on the merits, but before receipt of a final Office action or a Notice of Allowance.

The fee in the total amount of \$180 is being paid concurrently herewith on the Electronic Filing System (EFS) by way of Deposit Account authorization.

Please apply any other charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 17738-003001.

Respectfully submitted,

Date: 7/11/2006



Janice L. Kugler
Reg. No. 50,429

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17738-003001	Application No. 10/728,195
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Lu et al.	
		Filing Date December 3, 2003	Group Art Unit 1648

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	A1						

Foreign Patent Documents or Published Foreign Patent Applications							
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes No
	B1						

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	C1	Alonso et al., "Biodegradable microspheres as controlled-release tetanus toxoid delivery systems," Vaccine 12:299-306 (1994)
	C2	Bagarazzi et al., "Nucleic acid-based vaccines as an approach to immunization against human immunodeficiency virus type-1," Curr. Top Microbiol. Immunol. 226:107-43 (1998)
	C3	Barnett et al., "The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region," J. Virol. 75:5526-40 (2001)
	C4	Barouch et al., "Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes," Nature 415(6869):335-9 (2002)
	C5	Boyer et al., "Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination," Nat. Med. 3(5):526-32 (1997)
	C6	Chakrabarti et al., "Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization," J. Virol. 76(11):5357-68 (2002)
	C7	Chapman, et al., "Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells," Nucleic Acids Res. 19:3979-3986 (1991)
	C8	Clements et al., "Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus," J. Virol. 69: 2737 (1995)
	C9	Cristillo et al., "Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine," Virology 346(1):151-68 (2006)
	C10	Eldridge et al., "Biodegradable microspheres as a vaccine delivery system," Molec. Immunol. 28:287-94 (1991)
	C11	Goulder et al., "Evolution and transmission of stable CTL escape mutations in HIV infection," Nature 412:334-338 (2001)
	C12	Goulder et al., "Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS," Nature Med. 3:212-217 (1997)
	C13	Hu et al., "The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses," Clin. Exp. Immunol. 113:235-43 (1998)
	C14	Hurwitz et al., "Application of the polyvalent approach to HIV-1 vaccine development," Curr. Drug Targets Infect. Disord. 5(2):143-56 (2005)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17738-003001	Application No. 10/728,195
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Lu et al.	
		Filing Date December 3, 2003	Group Art Unit 1648

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	C15	Johnston and Flores, "Progress in HIV vaccine development," Curr. Op. In. Pharmac. 1:504-510 (2001)
	C16	Jones et al., "Protection of mice from Bordetella pertussis respiratory infection using microencapsulated pertussis fimbriae," Vaccine 13(7):675-81 (1995)
	C17	Kensil, et al., "QS-21 and QS-7: purified saponin adjuvants," Dev. Biol. Stand. 92:41-7 (1998)
	C18	Kong et al., "Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines," J. Virol. 77:12764-772 (2003)
	C19	Letvin et al., "Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines," Proc. Natl. Acad. Sci. USA 94(17):9378-83 (1997)
	C20	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	